BRPI0212775B8 - composto de 1,2,4-triazol e medicamento - Google Patents

composto de 1,2,4-triazol e medicamento

Info

Publication number
BRPI0212775B8
BRPI0212775B8 BRPI0212775A BR0212775A BRPI0212775B8 BR PI0212775 B8 BRPI0212775 B8 BR PI0212775B8 BR PI0212775 A BRPI0212775 A BR PI0212775A BR 0212775 A BR0212775 A BR 0212775A BR PI0212775 B8 BRPI0212775 B8 BR PI0212775B8
Authority
BR
Brazil
Prior art keywords
group
compound
triazole
hyperuricemia
therapeutic agent
Prior art date
Application number
BRPI0212775A
Other languages
English (en)
Other versions
BR0212775A (pt
BRPI0212775B1 (pt
Inventor
Nakamura Hiroshi
Matsumoto Koji
Ashizawa Naoki
Kaneda Soichi
Sato Takahiro
Iwanaga Takashi
Inoue Tsutomu
Original Assignee
Fuji Yakuhin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fuji Yakuhin Co Ltd filed Critical Fuji Yakuhin Co Ltd
Publication of BR0212775A publication Critical patent/BR0212775A/pt
Publication of BRPI0212775B1 publication Critical patent/BRPI0212775B1/pt
Publication of BRPI0212775B8 publication Critical patent/BRPI0212775B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"compostos de 1,2,4-triazol". é provido um novo composto de 1,2,4-triazol que é útil como um agente terapêutico para hiperuricemia e gota devido a hiperuricemia. um composto é representado pela seguinte fórmula geral (1): [substância química 6] em que r~ 2~ representa um grupo piridila não-substituído ou substituído, r~ 1~, representa um grupo piridila similar, um grupo piridina-n-óxido correspondente a estes grupos piridila, ou um grupo fenila, e r~ 3~ representa hidrogênio ou um grupo alquila inferior substituído por grupo pivaloilóxi e r~ 3~ se liga a um átomo de nitrogênio no anel. também são promovidos um processo para a produção de um composto por reação de uma nitrila e uma hidrazida, e um agente terapêutico, particularmente um inibidor de oxidase de xantina.
BRPI0212775A 2002-01-28 2002-12-03 composto de 1,2,4-triazol e medicamento BRPI0212775B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002017825 2002-01-28
PCT/JP2002/012662 WO2003064410A1 (en) 2002-01-28 2002-12-03 Novel 1,2,4-triazole compound

Publications (3)

Publication Number Publication Date
BR0212775A BR0212775A (pt) 2004-10-13
BRPI0212775B1 BRPI0212775B1 (pt) 2017-06-06
BRPI0212775B8 true BRPI0212775B8 (pt) 2021-05-25

Family

ID=27653386

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0212775A BRPI0212775B8 (pt) 2002-01-28 2002-12-03 composto de 1,2,4-triazol e medicamento

Country Status (21)

Country Link
US (1) US7074816B2 (pt)
EP (1) EP1471065B1 (pt)
JP (1) JP3600832B2 (pt)
CN (1) CN1561340B (pt)
AR (1) AR042602A1 (pt)
AT (1) ATE387438T1 (pt)
AU (1) AU2002349754B2 (pt)
BR (1) BRPI0212775B8 (pt)
CA (1) CA2462132C (pt)
DE (1) DE60225341T2 (pt)
DK (1) DK1471065T3 (pt)
ES (1) ES2300486T3 (pt)
MX (1) MXPA04004037A (pt)
NO (1) NO326941B1 (pt)
NZ (1) NZ531673A (pt)
PL (1) PL208260B1 (pt)
PT (1) PT1471065E (pt)
RU (1) RU2293733C2 (pt)
TW (1) TWI257926B (pt)
WO (1) WO2003064410A1 (pt)
ZA (1) ZA200401777B (pt)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2531912A1 (en) * 2003-07-24 2005-02-03 Fujiyakuhin Co., Ltd. Process for producing 1,2,4-triazole compound and intermediate therefor
US20060189811A1 (en) * 2004-07-23 2006-08-24 Fujiyakuhin Co., Ltd. Process for producing 1,2,4-triazole compound and intermediate therefor
WO2006121995A2 (en) 2005-05-09 2006-11-16 Tap Pharmaceutical Products, Inc. Methods for treating nephrolithiasis
WO2007019153A2 (en) * 2005-08-03 2007-02-15 Tap Pharmaceutical Products, Inc. Methods for treating hypertension
CA2623327A1 (en) * 2005-10-07 2007-04-19 Kissei Pharmaceutical Co., Ltd. Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same
EP3219319A1 (en) * 2006-06-22 2017-09-20 Nippon Chemiphar Co., Ltd. Agent for overcoming resistance to anti-cancer agent
WO2008010315A1 (en) 2006-07-19 2008-01-24 Nippon Medical School Foundation Therapeutic agent for amyotrophic lateral sclerosis
CA2669935A1 (en) * 2006-11-13 2008-05-29 Takeda Pharmaceuticals North America, Inc. Methods for preserving renal function using xanthine oxidoreductase inhibitors
US20090124623A1 (en) * 2006-11-13 2009-05-14 Christopher Lademacher Methods for preserving and/or increasing renal function using xanthine oxidoreductase inhibitors
RU2009131454A (ru) * 2007-01-19 2011-02-27 Такеда Фармасьютикалз Норт Америка, Инк. (Us) Способы предупреждения или уменьшения числа обострений подагры с применением ингибиторов ксантиноксидоредуктазы и противовоспалительных средств
JO2784B1 (en) * 2007-10-18 2014-03-15 شركة جانسين فارماسوتيكا ان. في 5,3,1 - Triazole substitute derivative
BRPI0819847B1 (pt) 2007-11-27 2022-01-11 Ardea Biosciences, Inc Compostos e composições
EP2165705A1 (en) 2008-09-18 2010-03-24 Centre National de la Recherche Scientifique (CNRS) Use of a compound capable of reducing the uric acid level for the prevention and/or the treatment of lung inflammation and fibrosis
US20100311756A1 (en) * 2009-01-22 2010-12-09 Takeda Pharmaceuticals North America, Inc. Methods for delaying the progression of at least one of cardiac hypertrophy, cardiac remodeling or left ventricular function or the onset of heart failure in subjects in need of treatment thereof
RU2412180C1 (ru) * 2009-07-29 2011-02-20 Государственное образовательное учреждение высшего профессионального образования "Южно-Российский государственный технический университет (Новочеркасский политехнический институт)" Способ получения 3(5)-пиридилзамещенных 5(3)-амино-1,2,4-триазолов
JP5978216B2 (ja) 2010-09-10 2016-08-24 タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド テオフィリンとフェブキソスタットの併用療法のための方法
JP5862897B2 (ja) * 2010-11-01 2016-02-16 株式会社三和化学研究所 腎機能障害の予防又は治療に用いる医薬
JP5629380B2 (ja) 2010-12-17 2014-11-19 田辺三菱製薬株式会社 連続芳香環式化合物
US8541094B2 (en) 2011-03-01 2013-09-24 Empire Technology Development Llc Temperature controlled variable reflectivity coatings
RU2476428C1 (ru) * 2011-09-01 2013-02-27 Государственное образовательное учреждение высшего профессионального образования "Южно-Российский государственный технический университет (Новочеркасский политехнический институт)" Способ получения дигидрохлорида 5-амино-3-аминометил-1,2,4-триазола
ES2690315T3 (es) 2012-06-15 2018-11-20 Mitsubishi Tanabe Pharma Corporation Compuestos de imidazol y triazol como inhibidores de DGAT-1
ES2732360T3 (es) 2012-07-25 2019-11-22 Fuji Yakuhin Co Ltd Forma cristalina del 4-[5-(piridin-4-il)-1H-1,2,4-triazol-3-il]piridin-2-carbonitrilo
CA2876268C (en) 2012-07-25 2016-12-20 Fujiyakuhin Co., Ltd. Method for producing 4-[5-(pyridin-4-yl)-1h-1,2,4-triazol-3-yl]pyridine-2-carbonitrile
CN103724329B (zh) * 2013-12-23 2015-02-18 济南百诺医药科技开发有限公司 4-[5-(吡啶-4-基)-1h-[1,2,4]三唑-3-基]吡啶-2-甲腈的制备方法
CN104042577B (zh) * 2014-06-13 2016-08-24 安徽省逸欣铭医药科技有限公司 一种稳定的托匹司他片及其制备方法
CN105315260A (zh) * 2014-07-29 2016-02-10 北京海步医药科技股份有限公司 一种托布司他一水合物晶型及其制备方法
CN105367490B (zh) * 2014-08-18 2019-01-04 上海医药工业研究院 合成托吡司他的新中间体及其制备方法
CN105348264B (zh) * 2014-08-18 2018-01-16 上海医药工业研究院 一种托吡司他的合成方法
CN104151297B (zh) * 2014-08-27 2016-03-16 王庆本 4-[5-(吡啶-4-基)-1h-[1，2，4]三唑-3-基]吡啶-2-甲腈的制备方法
JP6684264B2 (ja) * 2015-02-17 2020-04-22 株式会社三和化学研究所 心不全の予防又は治療のための医薬
US10413546B2 (en) 2015-02-24 2019-09-17 National University Corporation Tottori University Drug for preventing and/or treating dementia
CN107531677A (zh) * 2015-02-25 2018-01-02 法尔玛赞公司 用于制备托匹司他及其中间体的方法
CN105693699B (zh) * 2015-03-30 2019-06-18 苏州晶云药物科技股份有限公司 托吡司他的晶型及其制备方法
CN104910068B (zh) * 2015-04-24 2017-07-14 南京医科大学 一种2‑氰基异烟酸酰肼1.5对甲苯磺酸盐的合成方法
CN106279111A (zh) * 2015-05-12 2017-01-04 北京济美堂医药研究有限公司 一种精制托吡司他的新方法
CN104961730B (zh) * 2015-06-18 2017-05-17 山东金城医药化工股份有限公司 托吡司他新晶型及其制备方法
CN105130958B (zh) * 2015-08-31 2017-10-31 济南康和医药科技有限公司 5‑(2‑氰基4‑吡啶基)‑3‑(4‑吡啶基)‑1,2,4‑三唑的制备工艺
CN105294656A (zh) * 2015-10-10 2016-02-03 大道隆达（北京）医药科技发展有限公司 一种托匹司他的制备工艺和方法
CN106336399A (zh) * 2015-11-03 2017-01-18 江苏悦兴药业有限公司 托匹司他工艺杂质的制备方法
CN105294584A (zh) * 2015-11-30 2016-02-03 中国医科大学 1-取代苯基-1h-1,2,3-三唑类化合物、制备方法及其用途
CN105399732A (zh) * 2015-12-07 2016-03-16 青岛正大海尔制药有限公司 一种托匹司他的制备方法
CN106008465A (zh) * 2016-03-16 2016-10-12 江苏悦兴药业有限公司 一种托匹司他杂质的合成方法
CN108250183A (zh) * 2016-12-29 2018-07-06 北京诚济制药有限公司 一种高纯度的托匹司他的制备方法
CN109721586B (zh) * 2017-10-27 2021-03-02 中国医科大学 一种5-苄基-3-吡啶基-1h-1,2,4-三唑类化合物及其制备方法和用途
CN107652271B (zh) * 2017-11-06 2020-06-16 上海中拓医药科技有限公司 一种托匹司他晶型i的制备方法
CN108017619B (zh) * 2017-12-06 2020-08-11 成都惟邦药业有限公司 一种托匹司他杂质及其制备方法
CN113354616B (zh) * 2020-03-05 2024-03-26 中国医学科学院药物研究所 二芳基-1,2,4-三唑类化合物及其制法和药物用途
CN113666909B (zh) * 2020-05-14 2024-07-02 鲁南制药集团股份有限公司 一种托匹司他的制备方法
CN114773262B (zh) * 2022-05-19 2024-05-07 兄弟科技股份有限公司 2-氰基-4-吡啶羧酸甲酯的合成方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7112373A (pt) * 1970-09-25 1972-03-28
US3882134A (en) * 1973-05-21 1975-05-06 Merck & Co Inc 1-Substituted-3,5-dipyridyl-1,2,4-triazoles
US3928361A (en) * 1973-05-21 1975-12-23 Merck & Co Inc 1-(Sulfamoylphenylalkyl)-3,5-dipyridyl-1,2,4 triazoles
US3947577A (en) * 1973-05-21 1976-03-30 Merck & Co., Inc. Anti-hyperuricemia composition
US3984558A (en) * 1973-05-21 1976-10-05 Merck & Co., Inc. 1,3,5-Trisubstituted-1,2,4-triazole compounds used as bronchodilators
US3963731A (en) * 1973-05-21 1976-06-15 Merck & Co., Inc. Pyridyl containing 1-benzenesulfonyl triazoles
US4104393A (en) * 1976-04-02 1978-08-01 Merck & Co., Inc. 1,3,5-Trisubstituted-1,2,4-triazole compounds
US5571897A (en) * 1991-12-05 1996-11-05 Wallac Oy Luminescent lanthanide chelates
JP3217846B2 (ja) * 1992-03-04 2001-10-15 クミアイ化学工業株式会社 トリアゾール誘導体及び殺虫剤
PT1123287E (pt) * 1998-10-23 2003-12-31 Dow Agrosciences Llc 1-(piridil substituido)-1,2,4-triazoles insecticidas
PL369598A1 (en) * 2001-02-21 2005-05-02 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists

Also Published As

Publication number Publication date
RU2004106554A (ru) 2005-07-27
AR042602A1 (es) 2005-06-29
JP3600832B2 (ja) 2004-12-15
EP1471065A1 (en) 2004-10-27
NO326941B1 (no) 2009-03-16
PL368672A1 (en) 2005-04-04
NZ531673A (en) 2006-06-30
DE60225341D1 (de) 2008-04-10
ATE387438T1 (de) 2008-03-15
EP1471065A4 (en) 2005-06-15
PT1471065E (pt) 2008-03-13
CN1561340A (zh) 2005-01-05
WO2003064410A1 (en) 2003-08-07
BR0212775A (pt) 2004-10-13
DK1471065T3 (da) 2008-03-25
TWI257926B (en) 2006-07-11
PL208260B1 (pl) 2011-04-29
CN1561340B (zh) 2012-05-23
NO20041075L (no) 2004-03-15
DE60225341T2 (de) 2009-04-09
HK1067132A1 (en) 2005-04-01
AU2002349754B2 (en) 2008-01-31
EP1471065B1 (en) 2008-02-27
CA2462132C (en) 2010-08-10
US7074816B2 (en) 2006-07-11
BRPI0212775B1 (pt) 2017-06-06
TW200302222A (en) 2003-08-01
RU2293733C2 (ru) 2007-02-20
CA2462132A1 (en) 2003-08-07
JPWO2003064410A1 (ja) 2005-05-26
US20050004175A1 (en) 2005-01-06
MXPA04004037A (es) 2004-07-23
ZA200401777B (en) 2005-08-31
ES2300486T3 (es) 2008-06-16

Similar Documents

Publication Publication Date Title
BR0212775A (pt) Composto de 1,2,4-triazol
TW200510381A (en) Novel 2-pyridinecarboxamide derivatives
BR0206433A (pt) Composto, composição farmacêutica, processo para a prepapação de um composto, e, uso de um composto
BR0312999A (pt) Compostos, composições farmacêticas, método para aumentar a cognição, de tratamento, de inibição da atividade de enzima pde4 em um paciente
NO20072605L (no) Nytt antranilinsyrederivat eller et salt derav
EA199800943A1 (ru) Производные мочевины и их применение в качестве ингибиторов инозин-5`-монофосфат- дегидрогеназы
NZ505968A (en) Sulfonylamino derivatives which inhibit matrix- degrading metallproteinases
EP1527049B8 (en) Fused heterocyclic compounds as peptidase inhibitors
BR0009167A (pt) Inibidores de enzima impdh
NO20020925L (no) N-heterosykliske derivater av NOS-inhibitorer
WO2002064547A3 (en) Isophthalic acid derivatives as matrix metalloproteinase inhibitors
WO2003033493A1 (en) ACTIVATOR FOR PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR δ
NZ330973A (en) Azolobenzazepine derivatives as neurologically active agents
AU7517400A (en) N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent
UA48937C2 (uk) Імідазолідини, заміщені гетероциклом, спосіб їх одержання і фармацевтична композиція, що їх містить
BRPI0509588A (pt) derivados e tetraidronaftiridina e um processo para preparação dos mesmos
WO2004012663A3 (en) Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme
NO20032731L (no) Fremgangsmåte for fremstilling av sulfonamid-substituerte imidazotriazinoner
HUP0003942A2 (hu) Helyettesített 3,3-diamino-2-propén-nitrilek, előállításuk és alkalmazásuk
DE60015390D1 (de) Antidiabetische thiazolidindione und ihre herstellung
EP1794120A4 (en) peptidase
HUP0201475A2 (hu) Heteroarilamidin-, metilamidin- és guanidinszármazékok, előállításuk és alkalmazásuk, valamint e vegyületeket tartalmazó gyógyászati készítmények
MX2007007025A (es) Nuevos derivados de hidantoina como inhibidores de metaloproteinasa.
DE60316436D1 (de) Amidderivate als inhibitoren der enzymatischen aktivität von renin
DK1165491T3 (da) LTA4-hydrolase-inhibitorer

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/12/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 20A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2699 DE 27-09-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.